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2557(tPVR). tPVR procedures are in their infancy with
few reports available on which to base an expert
consensus statement. Therefore, many of these recom-
mendations are based on expert consensus and the few
reports available. As the procedures evolve, technology
advances, experience grows, and more data accumulate,
there will certainly be a need to update this consensus
statement. The writing committee and participating so-
cieties believe that the recommendations in this report
serve as appropriate requisites. In some ways, these rec-
ommendations apply to institutions more than to in-
dividuals. There is a strong consensus that these new
valve therapies are best performed using a Heart Team
approach; thus, these credentialing criteria should be
applied at the institutional level. Partnering societies
used the ACC’s policy on relationships with industry (RWI)
and other entities to author this document (http://www.
acc.org/guidelines/about-guidelines-and-clinical-documents).
To avoid actual, potential, or perceived conﬂicts of in-
terest due to industry relationships or personal interests,
all members of the writing committee, as well as peer
reviewers of the document, were asked to disclose all
current healthcare-related relationships including those
existing 12 months before the initiation of the writing
effort. A committee of interventional cardiologists and
surgeons was formed to include a majority of members
with no relevant RWI and to be led by an interventional
cardiology cochair and a surgical cochair with no relevant
RWI. Authors with relevant RWI were not permitted to
draft or vote on text or recommendations pertaining to
their RWI. RWI were reviewed on all conference calls and
updated as changes occurred. Author and peer reviewer
RWI pertinent to this document are disclosed in
Appendices AI and AIII, respectively. In addition, to
ensure complete transparency, authors’ comprehensive
disclosure information (including RWI not pertinent to
this document) is available in Appendix AII. The work of
the writing committee was supported exclusively by the
partnering societies without commercial support. SCAI,
AATS, ACC, and STS believe that adherence to these
recommendations will maximize the chances that these
therapies will become a successful part of the armamen-
tarium for treating valvular heart disease in the United
States. In addition, these recommendations will hope-
fully facilitate optimum quality during the delivery of
this therapy, which will be important to the development
and successful implementation of future, less invasive
approaches to structural heart disease.
INTRODUCTION
Enabled by the development of new technologies, treat-
ment of valvular heart disease by transcatheter tech-
niques has complemented standard surgical approaches,thus providing enhanced care for our patients. Trans-
catheter techniques offer a less invasive treatment for
patients who were previously treatable only with open-
heart surgery or, in many cases, who were not treat-
able at all. Recognition from the medical community of
the applicability, effectiveness, and practicality of
transcatheter valve therapies has further increased in-
terest in these treatments. Training program content,
standards, credentialing, and board certiﬁcations for
cardiac surgical procedures and percutaneous coronary
intervention are well developed, but no such structure
exists in the ﬁeld of percutaneous structural or valvular
heart disease therapies. The purpose of this article is to
outline criteria for operator and institutional re-
quirements, to help enable institutions and providers to
participate responsibly in this new and rapidly devel-
oping ﬁeld.
The emergence of transcatheter pulmonic valve im-
plantation as an alternative to traditional surgical therapy
for valvular diseases has been facilitated by innovative
devices, rapidly developing techniques, and careful pa-
tient selection. The combination of interventional skills,
equipment, collaborative clinical management, surgical
approaches, techniques, and decision making distin-
guishes the qualiﬁcations to participate in this ﬁeld as
unique, as does the complexity of the patients who
require these therapies. Given both the high-risk nature of
these catheter interventions and the availability of
established alternative treatment options using tradi-
tional surgical approaches, several considerations are
important for institutions and operators planning to
implement these new technologies.
Deﬁning operator and institutional requirements for
these novel therapies is an important ﬁrst step to ensure
their optimal implementation. Part 1 of this series con-
cerning transcatheter aortic valve replacement (TAVR)
was previously published. The authors felt that the facil-
ities and institutional requirements have remained un-
changed; thus, those sections have not been repeated
here and may be found in the previous report (1).
PULMONIC VALVE REPLACEMENT
Some congenital cardiac defects require surgical recon-
struction of the right ventricular outﬂow tract (RVOT).
This procedure may entail pulmonic valve replacement or
placement of a pulmonic valve/conduit between the right
ventricle (RV) and pulmonary artery.
Over time, these reconstructions often develop valve
dysfunction, leading to pulmonary regurgitation and/or
stenosis. Pulmonary stenosis and/or regurgitation may
lead to right ventricular dysfunction associated with ex-
ercise intolerance, dysrhythmias, heart failure, and an
increased risk of sudden cardiac death (2). Biological
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commonly in children and young adults. Given the limits
of the durability of biological valves, these patients are
likely to undergo serial open-heart surgical procedures
over the course of their lifetimes.
Treatment of RVOT stenosis in patients following te-
tralogy of fallot (TOF) repair or for those with a conduit
between the RV and the pulmonary artery with balloon
dilatation has been used with limited and often short-
lived success. RVOT conduit stenting has been shown to
decrease RV pressure and to extend conduit lifespan (3,4).
However, this treatment option usually produces free
pulmonary regurgitation, which may be severe as the
leaﬂets of the previously placed valve/conduit are
rendered incompetent by the stent. Severe pulmonary
regurgitation has signiﬁcant long-term deleterious effects
including progressive RV dilation and dysfunction, dys-
rhythmias, and sudden cardiac death (2). ACC/AHA 2014
focused guidelines for management of patients with
valvular heart disease and ACC/AHA 2014 guidelines for
the management of adults with congenital heart disease
(5,6) provided the indications for pulmonary valve
replacement for pulmonary regurgitation in postoperative
patients with TOF: symptoms associated with severe pul-
monary insufﬁciency or in the absence of symptoms,
magnetic resonance imaging (MRI) criteria for severe pul-
monary insufﬁciency including: RVEDV of >150 ml/m2;
pulmonary regur-gitant fraction >40% and RV ejection
fraction <40%.
The operative risk is acceptably low (0.9–1.2%) for the
ﬁrst operation to implant a RV–pulmonary artery conduit
(7,8). A recent report from Ong et al. (7) demonstrated that
freedom from reoperation increased with successive in-
terventions from 50% at 10 years following implantation
of the ﬁrst conduit to 74% and 86% at 10 years for the
second and third conduit replacement, respectively.
Pulmonary homograft replacement during the Ross pro-
cedure was associated with even greater durability with
a reintervention incidence of 1 in 150 patient-years (9),
and reoperative rates seem to be lower with larger con-
duits (10). Patients may require multiple operations
over a lifetime, as the mean time to reoperation is about
10.3 years for xenografts and 16 years for homografts
(11,12). Tweddell et al. (11) reported that at about 1–2 years
after homograft replacement, 16% of patients had conduit
dysfunction and at about 4–5 years, almost 50% of the
homografts were dysfunctional. In that article, 25% of the
patients had reoperations at about 4–5 years after conduit
replacement. These reoperations are often complex
and involve increasing morbidity (blood transfusions,
medi-astinitis, etc.) and mortality over time (13).
Currently, there is no established or validated operative
risk calculator or score for pulmonary valve replacement.
Thus, assessment of operative risk is highly limited toclinical judgment of the operator, which may be inaccu-
rate due to bias.
The potential need for repeat surgery in this patient
population makes transcatheter pulmonic valve replace-
ment (tPVR) to replace an obstructed and/or regurgitant
pulmonary bioprosthesis or conduit an attractive option.
In 2000, Bonhoeffer et al. (14,15) reported the ﬁrst ex-
perimental and clinical human application of a trans-
catheter valve in the pulmonary position in a 12-year-old
patient with a previously implanted conduit for pulmo-
nary atresia. In 2005, in a compassionate use case, a
transcatheter pulmonary valve (Edwards SAPIEN valve;
Edwards Lifesciences, Irvine, CA) was placed in a 16-year-
old boy with congenital severe aortic stenosis who had
undergone a Ross operation (16).
Since then, more than 6,000 patients have received
percutaneously placed pulmonary valves (Ms. Jill
Hen-nesen, Medtronic Inc., personal communication).
Few reports from outside the United States have been
published (17,18). In 2010, the Melody valve (Medtronic
Corporation, Minneapolis, MN) was approved by the
United States Food and Drug Administration (FDA) under
Humanitarian Device Exemption (19,20). In January 2015,
the Melody valve received full premarket approval (PMA).
The SAPIEN valve is currently being used outside the
United States (21) and is under clinical investigation in the
United States for use in the RVOT (COMPASSION trial;
Edwards Lifesciences) (22). Currently, there are no data
published in the literature to indicate the total number of
percutaneous pulmonary valves implanted in the United
States. Furthermore, no data are published on the average
number of procedures performed by various operators/
institutions. Such data will be important to collect going
forward. With current valve technology, pretreatment of
the RVOT with bare metal stent implantation appears to
offer several advantages including: creation of a landing
zone for valve placement, elimination of conduit stenoses
prior to the valve implant and a decrease in the incidence
of stent/valve fracture that may lead to early valve failure
(20,22). For detailed technical aspects of the procedure,
the readers are referred to a chapter written by one of
the authors of this document (23). The procedure in gen-
eral is safe; however, there are potential complications
that can be encountered during or after the procedure.
The rate of serious complications in the US Melody trial
(19,20) was reported at 6%, including death from coronary
dissection (n ¼ 1), conduit rupture (n ¼ 1), unstable
arrhythmia (n ¼ 1), wire perforation in distal pulmonary
artery (n ¼ 2), and femoral vein thrombosis (n ¼ 1). In
the COMPASSION trial (22), the rate of serious complica-
tions was 21% (7 patients). Valve or stent migration
occurred in four patients (three requiring surgical
retrieval and one was deployed in the inferior vena cava),
unstable arrhythmias in one patient, and self-limited wire
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2559perforation in the distal pulmonary arteries in two
patients. These complications can be divided into the
following: procedural: pulmonary hemorrhage (secondary
to guide wire); ventricular arrhythmias; stent emboliza-
tion (prestenting); coronary artery compression (24);
conduit rupture and valve embolization. Complications at
follow-up: stent fracture and infective endocarditis (25).
While these complications were initially reported to be as
high as 12% in early smaller tPVR studies (17), more recent
trials have shown a decrease of these adverse events to
5–6% (20). This decrease in procedural complications
is most likely due to increased operator experience.
In 2008, Bon-hoeffer’s group published a study looking
at the learning curve for tPVR since it was ﬁrst used
in 2001. They reported that after their initial 50 patients,
the incidence of procedural complications fell to 2.9%
(18). Institutions/operators that desire to embark on
trans-catheter pulmonary valve implantation should
meet certain requirements:
Institutional Requirements
Table I summarizes the institutional and operator re-
quirements to embark on tPVR. These include but are not
limited to the following:
1. Cardiac cases requirements
The institution should perform 150 congenital/struc-
tural catheterization procedures per year. Of those, 100
should be interventional in nature, including but not
limited to stenting of branch pulmonary arteries and
RVOT. The rationale for this number is the large number
of various procedures performed in a congenital labora-
tory and the need for large number of inventory products.
Furthermore, the institution should perform a minimum
of a 100 open-heart surgical procedures in patients with
congenital heart disease (if a Children’s hospital) or an
adult program associated with a Children’s hospital. The
adult program should perform a minimum of 25 adult-
congenital surgical cases per year.TABLE I Characteristic of tPVR Program
Institutional cath volume 150 congenital/structural heart disease ca
Interventionalist 100 diagnostic and therapeutic cases/yea
Experience with stent implantation for br
or the equivalent in interventional car
Device training Suitable training on devices to be used
Surgical program The program is or is associated with a co
or the program is an adult-congenital
There should be ECMO capabilities in the
Data registry All cases must be submitted to a nationa
Existing programs Programs that have already performed 10
New programs New programs should have sufﬁcient vol
Outcomes Patients should have 80% freedom from2. Stafﬁng requirements
The institution should have a Heart Team (interven-
tional cardiologists (pediatric trained or adult trained, as
long as they have the expertise in this area), cardiac sur-
geons, noninvasive cardiologists, cardiac anesthesiolo-
gists, cardiovascular radiologists, and others) that is
actively engaged in the treatment of congenital and/or
structural heart disease. The Heart Team should have
experience in the treatment of conditions of the pulmo-
nary valve and the RVOT. Each case should be discussed
among the Heart Team members (medical-surgical con-
ference) and the best approach for each patient is
determined.
Furthermore, the institution should have extracorpo-
real membrane oxygenation ECMO capabilities for the
rare patient who may require such support.
3. Imaging requirements
a. Echocardiographic laboratory: transthoracic and
transesophageal echocardiographic capabilities with
sonographers and echocardiographers experienced
in congenital heart disease.
b. Radiologic imaging: cardiac CT and cardiac MRI
capabilities.
c. Cardiovascular catheterization laboratory or hybrid
suite equipped with a ﬁxed X-ray system with ﬂuo-
roscopy offering high-resolution imaging, recording
and archiving capability. A biplane unit is desirable.
d. Hemodynamic evaluation, recording and retrieval
capabilities.
e. The institution should be a participant in a national
registry (IMPACT) collecting data on all patients
undergoing transcatheter pulmonary valve replace-
ment, in a manner similar to sites performing TAVR.
The professional societies will determine the exact
registry that will collect data on patients undergo-
ing tPVR to follow the outcomes of such patients
and, hopefully, to compare these outcomes toths/year
r including 50 congenital/structural heart intervention cases/year
anch pulmonary arteries and conduit stenosis Board certiﬁed/eligible
diology, pediatric cardiology, or thoracic surgery
ngenital/structural open-heart program that performs >100 open surgical cases
cardiac program that performs 25 adult-congenital cardiac operations/year
institution for the rare case when needed
l clinical database
tPVR procedures may be considered established
ume to perform 5 cases per year or 10 over the ﬁrst 2 years
reintervention at 1 year
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2560patients who undergo the traditional surgical
approach.
f. ECMO: availability of ECMO support for the rare case
when needed.
Operator Requirements
The individual operator interested in performing tPVR
should meet the following criteria:
1. The operator performs congenital and/or structural
heart interventions. In addition to experience with
balloon valvuloplasty, experience in stenting of branch
pulmonary arteries and RVOT is needed for the treat-
ment of complex lesions. To minimize the risk of cor-
onary artery compression, the operator should have
full knowledge and experience assessing the location
of the coronary arteries in relation to the RVOT. This
assessment is crucial in every patient who undergoes
percutaneous pulmonary valve implantation (24). The
authors encourage collaboration with adult cardiolo-
gists when assessing the coronary arteries relation to
the RVOT.
2. The operator should perform at least 100 diagnostic/
interventional cases per year, 50 of which should be
interventional (congenital/structural) cases per year.
The rationale for demanding higher number than whatwe have published in the tAVR document is the fact
that tPVR is a much more demanding procedure than
tAVR or even percutaneous mitral valve repair. tPVR is
a more challenging procedure with more potential
serious complications, including stent embolization
that requires certain skills in retrieving embolized
foreign body, rupture of the branch pulmonary arteries
that may lead to catastrophic consequences, and
rupture of the RVOT that may lead to tamponade and
death. Finally, compression of the coronary arteries
induced by stenting the RVOT may occur and may lead
to death. Based on this, the writing committee felt that
the operator interested in performing tPVR should
practice more cases on annual basis.
3. The operator should attend a peer-to-peer training
course as recommended by the United States FDA.
Such courses should discuss the procedure in detail
(selection of patients; baseline assessment; procedural
technique; potential complications and their manage-
ment and how to avoid such complications).
4. The operator should perform a simulated case if available.
5. At a minimum, the ﬁrst three cases should be per-
formed under the supervision of a proctor. Proctorship
is essential in tPVR and at the end of the proctoring
session the trainee should be cleared by the proctor to
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